OncoSil Medical Limited (ASX: $OSL) Pancreatic cancer treatment device company, has announced its availability at eleven prestigious hospitals across Spain. This expansion signifies a significant step towards increased accessibility of this innovative treatment for cancer patients in the region.

In the recently published half-yearly report, they said that in Spain a total of 20 patients have received treatment in clinical trials and commercial settings and they are continuously expanding by adding new sites. Recently big news was that 84 German hospitals received approval from the German Institute for the Hospital Remuneration System (InEK) to discuss funding for the OncoSil device under the innovation funding.

Here are the details of the 11 hospitals in Spain in which OncoSil is available.

Hospitals in Spain

Madrid 

OncoSil is available in 4 hospitals in Madrid, all other places have only one hospital each:

1. Ramón y Cajal University Hospital
2. HM Sanchinarro University Hospital
3. Hospital La Paz
4. Hospital 12 de octubre

Barcelona

1. Vall d'Hebron University Hospital
2. Fuenlabrada
3. Hospital Universitario de Fuenlabrada

Las Palmas de Gran Canaria

1. Hospital Materno Infantil de Gran Canaria
2. Majadahonda
3. Puerta de Hierro Majadahonda University Hospital

Pamplona

1. Clínica Universidad de Navarra 
2. Valladolid
3. University Clinical Hospital of Valladolid

Valencia

1. Doctor Peset University Hospital

These hospitals now offer OncoSil as a treatment option for patients. OncoSil is in the process of broadening its availability and conducting further trials, indicating its potential to offer an improved approach to treating pancreatic cancer compared to conventional methods. This expansion is beneficial for both patients and the company's investors. With significant innovations and operational strengths, OncoSil has the potential to grow into a major biotech entity.